Close

move up move left move right move bottom

Watch NASCAR® driver Brian Vickers tell his story

XARELTO® (rivaroxaban) Information for Healthcare Professionals

The #1 prescribed novel oral anticoagulant in the US*1

*Among Factor Xa inhibitors and direct thrombin inhibitors.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

INDICATIONS

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

Reference:

  1. Data on file. Janssen Pharmaceuticals, Inc. Based on IMS Health. NPA Weekly, April 2015.